AbbVie (ABBV) Operating Expenses (2012 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at AbbVie was $47.52 billion, up 0.3% year-over-year; for FY2025, it came in at $46.09 billion, down 2.4% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 6.0% (FY2020 to FY2025).
• In prior years, AbbVie's Operating Expenses was $47.2 billion in FY2024 (+13.6%), $41.56 billion in FY2023 (+4.1%), $39.94 billion in FY2022 (+4.3%) and $38.27 billion in FY2021 (+11.1%).
• Quarterly Operating Expenses has run from a low of $8.82 billion in Q1 2022 to a high of $16.59 billion in Q4 2024 over five years.
• On a year-over-year basis, Operating Expenses increased in six of the last eight quarters, with growth averaging 7.6%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2024, with growth of 49.4%; the weakest was Q4 2025, with a decline of 27.2%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $11.01 billion (Q1 2026), $12.07 billion (Q4 2025) and $13.87 billion (Q3 2025).